Longeveron (LGVN) Expected to Announce Quarterly Earnings on Thursday

Posted by on May 5th, 2026

Longeveron (NASDAQ:LGVN – Get Free Report) is expected to announce its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $0.3740 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Longeveron (NASDAQ:LGVN – Get Free Report) last issued its earnings results on Tuesday, March 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.20. The business had revenue of $0.37 million during the quarter, compared to the consensus estimate of $0.11 million. Longeveron had a negative return on equity of 199.79% and a negative net margin of 1,893.58%. On average, analysts expect Longeveron to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Longeveron Price Performance

Shares of LGVN traded up $0.00 during mid-day trading on Tuesday, hitting $0.87. The company’s stock had a trading volume of 48,830 shares, compared to its average volume of 4,136,361. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.03. Longeveron has a 1-year low of $0.48 and a 1-year high of $1.80. The firm has a market capitalization of $20.13 million, a P/E ratio of -0.68 and a beta of -0.31. The firm has a 50-day simple moving average of $0.89 and a 200 day simple moving average of $0.72.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on LGVN. Wall Street Zen cut Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright decreased their target price on shares of Longeveron from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Longeveron in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $5.50.

Check Out Our Latest Report on Longeveron

Hedge Funds Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd acquired a new stake in Longeveron Inc. (NASDAQ:LGVN – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron at the end of the most recent reporting period. Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

(Get Free Report)

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.

Featured Stories

Earnings History for Longeveron (NASDAQ:LGVN)

Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.